Could The Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) Ownership Structure Tell Us Something Useful?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!
Every investor in Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. We also tend to see lower insider ownership in companies that were previously publicly owned.
With a market capitalization of US$26m, Pernix Therapeutics Holdings is a small cap stock, so it might not be well known by many institutional investors. Taking a look at the our data on the ownership groups (below), it’s seems that institutions are noticeable on the share registry. We can zoom in on the different ownership groups, to learn more about PTX.
View our latest analysis for Pernix Therapeutics Holdings
What Does The Institutional Ownership Tell Us About Pernix Therapeutics Holdings?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it’s included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
Pernix Therapeutics Holdings already has institutions on the share registry. Indeed, they own 8.3% of the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Pernix Therapeutics Holdings, (below). Of course, keep in mind that there are other factors to consider, too.
Our data indicates that hedge funds own 7.4% of Pernix Therapeutics Holdings. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Our information suggests that there isn’t any analyst coverage of the stock, so it is probably little known.
Insider Ownership Of Pernix Therapeutics Holdings
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Our data suggests that insiders own under 1% of Pernix Therapeutics Holdings, Inc. in their own names. It seems the board members have no more than US$209k worth of shares in the US$26m company. Many tend to prefer to see a board with bigger shareholdings. A good next step might be to take a look at this free summary of insider buying and selling.
General Public Ownership
The general public, mostly retail investors, hold a substantial 84% stake in PTX, suggesting it is a fairly popular stock. This size of ownership gives retail investors collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.
Next Steps:
It’s always worth thinking about the different groups who own shares in a company. But to understand Pernix Therapeutics Holdings better, we need to consider many other factors.
I like to dive deeper into how a company has performed in the past. You can find historic revenue and earnings in this detailed graph.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
To help readers see past the short term
volatility of the financial market, we aim to bring you a long-term
focused research analysis purely driven by fundamental data. Note
that our analysis does not factor in the latest price-sensitive
company announcements.
The author is an independent contributor and at the time of
publication had no position in the stocks mentioned. For errors
that warrant correction please contact the editor at
[email protected].